Skip to main
OSTX
OSTX logo

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. is strategically poised for growth due to its effective positioning within the expanding osteosarcoma market, which boasts a projected revenue potential of $500 million for its lead asset, OST-HER2. The company has successfully secured a key patent that extends market exclusivity to 2040, enhancing its competitive advantage as it seeks fast-track and orphan drug designations for its treatments. Additionally, positive preclinical and clinical data, along with strong financial stability and regulatory momentum, bolster the company's efforts to attract investment and forge strategic collaborations, effectively positioning it for future commercialization and growth in the oncology sector.

Bears say

OS Therapies Inc continues to experience challenges in advancing its clinical pipeline, which may hinder its ability to generate future revenue streams. The company's financial reports indicate a substantial burn rate, resulting in significant cash outflows that could jeopardize its operational sustainability without additional funding. Furthermore, the lack of partnerships or collaborations to support its drug development efforts raises concerns about the potential for successful commercialization in a highly competitive market.

OSTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, OSTX has a Strong Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.